Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.

被引：0
|
作者：
Piedra, A. [1 ]
Barba Joaquin, A. [1 ]
Mosquera Martinez, J. [2 ]
Fernandez Bruno, M. [2 ]
Cordeiro Gonzalez, P. [3 ]
Sullivan, I. G. [1 ]
Riudavets Melia, M. [1 ]
Aguado Sorolla, M. [1 ]
Gallardo Melo, P. [1 ]
Martin Cullell, B. [4 ]
Gavira, J. [1 ]
Tapia, J. C. [1 ]
Romano, A. [1 ]
Bosma, F. [5 ]
Sanchez Del Rio, S. [1 ]
Sanz Beltran, J. [1 ]
Molina Perez, M. A. [6 ]
Serra Lopez, J. [1 ]
Garcia Campelo, M. R. [7 ]
Majem Tarruella, M. [1 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[2] CHUAC Complexo Hosp Univ A Coruna, Med Oncol Serv Dept, La Coruna, Spain
[3] CHUAC Complexo Hosp Univ A Coruna, Oncol Dept, La Coruna, Spain
[4] Hosp Santa Creu & Sant Pau, Dept Oncol, Barcelona, Spain
[5] Hosp Santa Creu & Sant Pau, Oncol, Barcelona, Spain
[6] Hosp Santa Creu & Sant Pau, Oncol Med, Barcelona, Spain
[7] Inst Invest Biomed A Coruna INIBIC, Dept Med Oncol, La Coruna, Spain
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1223
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1098P
引用
收藏
页码：S1053 / S1053
页数：1
相关论文
共 50 条
  • [41] The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis
    Aguiar, Pedro, Jr.
    Lopes, Gilberto
    Santoro, Ilka
    Tadokoro, Hakaru
    Barreto, Carmelia
    De Mello, Ramon
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S171 - S172
  • [42] Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients with High PD-L1 Expression in Singapore
    Tan, W. L.
    Huang, M.
    Chandwani, S.
    Hsu, T.
    Tan, S. C.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S630 - S630
  • [43] Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC
    Takeyasu, Yuki
    Yoshida, Tatsuya
    Shibaki, Ryota
    Matsumoto, Yuji
    Goto, Yasushi
    Kanda, Shintaro
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Motoi, Noriko
    Ohe, Yuichiro
    CLINICAL LUNG CANCER, 2021, 22 (02) : 127 - +
  • [44] Efficacy of Immune-Checkpoint Inhibitors and EGFR-TKIs in NSCLC Patients with High PD-L1 Expression
    Masuda, K.
    Horinouchi, H.
    Tanaka, M.
    Higashiyama, R.
    Shinno, Y.
    Sato, J.
    Yoshida, T.
    Matsumoto, Y.
    Goto, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S292 - S293
  • [45] T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer
    Shah, Manish A.
    Kojima, Takashi
    Hochhauser, Daniel
    Enzinger, Peter
    Raimbourg, Judith
    Hollebecque, Antoine
    Lordick, Florian
    Kim, Sung-Bae
    Tajika, Masahiro
    Lockhart, Albert Craig
    Arkenau, Hendrick-Tobias
    El-Hajbi, Farid
    Gupta, Mukul
    Pfeiffer, Per
    Bhagia, Pooja
    Cao, Zhu Alexander
    Lunceford, Jared
    Suryawanshi, Shailaja
    Ayers, Mark
    Marton, Matthew J.
    Kato, Ken
    FUTURE ONCOLOGY, 2022, 18 (25) : 2783 - 2790
  • [46] Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
    Soomin Ahn
    Jong- chan Lee
    Dong Woo Shin
    Jaihwan Kim
    Jin‑ Hyeok Hwang
    Scientific Reports, 10
  • [47] Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC
    John, Nikolaus
    Schlintl, Verena
    Sassmann, Teresa
    Lindenmann, Joerg
    Fediuk, Melanie
    Wurm, Robert
    Douschan, Philipp
    Zacharias, Martin
    Kalson, Lipika
    Posch, Florian
    Absenger, Gudrun
    Brcic, Luka
    Jost, Philipp J.
    Terbuch, Angelika
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
  • [48] Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
    Chen, Ya
    Wang, Yanan
    Yang, Zhengyu
    Hu, Minjuan
    Zhang, Yanwei
    Qian, Fangfei
    Zhang, Wei
    Zhang, Bo
    Han, Baohui
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [49] BUDGET IMPACT MODEL OF PEMBROLIZUMAB IN PREVIOUSLY TREATED ADVANCED PD-L1 NSCLC POSITIVE IN COLOMBIA
    Huang, M.
    Arunachalam, A.
    Chandwani, S.
    Monsanto, H.
    Beltran, C.
    Rojas, M.
    Hinestrosa, F.
    Restrepo, M.
    Ordosgoitia, A.
    Martinez, I
    VALUE IN HEALTH, 2017, 20 (05) : A97 - A97
  • [50] Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
    Zhang, Jie
    Gao, Jing
    Li, Yanyan
    Nie, Jun
    Dai, Ling
    Hu, Weiheng
    Chen, Xiaoling
    Han, Jindi
    Ma, Xiangjuan
    Tian, Guangming
    Wu, Di
    Shen, Lin
    Fang, Jian
    THORACIC CANCER, 2015, 6 (04) : 534 - 538
12345